Literature DB >> 23134644

Identifying and ensuring optimal care for all children at risk of developing serious respiratory syncytial virus disease: a Canadian nurses' perspective.

Marianne Bracht1, Debbie Basevitz, Marilyn Cranis, Rose Paulley, Bosco Paes.   

Abstract

Globally, respiratory syncytial virus (RSV) infection causes substantial morbidity in infants and young children, particularly those with specific risk factors (e.g., prematurity, chronic lung and congenital heart disease). Supportive measures are the mainstay of care for RSV-related disease. In the absence of medical treatments, RSV prophylaxis (RSVP) with palivizumab is recommended for high-risk patients to help reduce the risk of developing serious disease. Geographic distances, language and cultural barriers, and other factors can impede effective education of caregivers regarding the potential impact of RSV disease and benefits of RSVP compliance. We present our experiences developing successful Canadian RSVP programs, organized through a dedicated coordinator or small group of health care staff. These programs focus on identifying all infants and young children eligible for RSVP, effectively educating health care staff and family caregivers, developing educational tools that consider language and cultural factors, and interdisciplinary collaboration and networking throughout the health care system.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23134644     DOI: 10.1891/0730-0832.31.6.369

Source DB:  PubMed          Journal:  Neonatal Netw        ISSN: 0730-0832


  3 in total

1.  Communication challenges between nurses and migrant paediatric patients.

Authors:  Beatrice Kaufmann; Tannys Helfer; Dana Pedemonte; Marika Simon; Sarah Colvin
Journal:  J Res Nurs       Date:  2020-05-03

2.  Clinical Decision Support and Palivizumab: A Means to Protect from Respiratory Syncytial Virus.

Authors:  L H Utidjian; A Hogan; J Michel; A R Localio; D Karavite; L Song; M J Ramos; A G Fiks; S Lorch; R W Grundmeier
Journal:  Appl Clin Inform       Date:  2015-12-30       Impact factor: 2.342

3.  The Logistics and Coordination of Respiratory Syncytial Virus Immunoprophylaxis Use Among US Pediatric Specialists.

Authors:  Pierre C Wong; Prabhu S Parimi; Joseph B Domachowske; Deborah M Friedman; Michael G Marcus; Daniel F Garcia; William V La Via; Iqra A Syed; Shelagh M Szabo; Kimmie K McLaurin; Veena R Kumar
Journal:  Clin Pediatr (Phila)       Date:  2016-01-08       Impact factor: 1.168

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.